Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.45 |
| ▸ | ACP1 | P24666 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20551540 | 0.91 | TP53 (0.50) | MAPTTP53HTTALDH1A1TSHR | |
| SCHEMBL21750810 | 0.91 | TP53 (0.50) | MAPTTP53HTTALDH1A1TSHR | |
| SCHEMBL28359727 | 0.88 | TP53 (0.48) | MAPTTP53HTTALDH1A1KDM4E | |
| SCHEMBL20551736 | 0.87 | JAK2 (0.52) | TP53HTTALDH1A1KDM4EHPGD | |
| SCHEMBL29887170 | 0.85 | TP53 (0.51) | MAPTTP53ABCB1ABCG2MKNK1 | |
| SCHEMBL31379875 | 0.82 | IGF1R (0.42) | MAPTHTTALDH1A1KDM4EHPGD | |
| SCHEMBL31379897 | 0.82 | JAK2 (0.42) | MAPTHTTALDH1A1KDM4EHPGD | |
| SCHEMBL21750686 | 0.82 | HTT (0.49) | MAPTHTTALDH1A1KDM4EHPGD | |
| SCHEMBL20551893 | 0.82 | HTT (0.49) | MAPTHTTALDH1A1KDM4EHPGD | |
| SCHEMBL20552141 | 0.81 | TP53 (0.50) | MAPTTP53ABCB1ABCG2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503456-B2 | Substituted pyrimidines and 1,3,5-triazines as RHOJ inhibitors | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-23 | — | — | US | disclosed |
| EP-3825310-B1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2025-11-12 | — | — | EP | disclosed |
| US-20240391898-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-11-28 | — | — | US | disclosed |
| US-11952366-B2 | Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-04-09 | — | — | US | disclosed |
| US-20220242848-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2022-08-04 | — | — | US | disclosed |
| US-11198682-B2 | Substituted pyrimidines as inhibitors for a Rho family of GTP-ases | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-12-14 | — | — | US | disclosed |
| US-11198682-B2 | Substituted pyrimidines as inhibitors for a Rho family of GTP-ases | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-12-14 | — | — | US | disclosed |
| EP-3619202-B1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2021-06-30 | — | — | EP | disclosed |
| EP-3619202-B1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2021-06-30 | — | — | EP | disclosed |
| EP-3825310-A1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | Fondazione Istituto Italiano di Tecnologia (IT) | 2021-05-26 | — | — | EP | disclosed |
| EP-3825310-A1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | Fondazione Istituto Italiano di Tecnologia (IT) | 2021-05-26 | — | — | EP | disclosed |
| EP-3619202-A1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | Fondazione Istituto Italiano di Tecnologia (IT) | 2020-03-11 | — | — | EP | disclosed |
| US-20200062733-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-02-27 | — | — | US | disclosed |
| US-20200062733-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-02-27 | — | — | US | disclosed |
| WO-2018203256-A1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952366-B2 | Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases | CDC42, RHOA, TNK2 | MAPT 1329/4885TP53 2062/4885HTT 2889/4885 |
| US-12503456-B2 | Substituted pyrimidines and 1,3,5-triazines as RHOJ inhibitors | TNK2, CDC42, CDC42BPA | MAPT 878/4885TP53 1329/4885HTT 3789/4885 |
| US-20200062733-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | CDC42, RHOA, RHOT2 | MAPT 1372/4885TP53 1479/4885HTT 3502/4885 |
| US-20240391898-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | CDC42, RHOA, RHOT2 | MAPT 1372/4885TP53 1479/4885HTT 3502/4885 |
| US-11198682-B2 | Substituted pyrimidines as inhibitors for a Rho family of GTP-ases | CDC42, TNK2, ARHGEF1 | MAPT 1109/4885TP53 942/4885HTT 3174/4885 |
| US-20220242848-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | CDC42, RHOA, RHOT2 | MAPT 1372/4885TP53 1479/4885HTT 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.